ArticleFrontiers in oncology2026
Beyond the platform: why surgical quality and surgeon proficiency outweigh the RATS vs. VATS debate in early-stage lung cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The debate regarding the oncological superiority of Robotic-Assisted Thoracic Surgery (RATS) versus Video-Assisted Thoracic Surgery (VATS) for early-stage lung cancer is ongoing. Current evidence suggests comparable oncological outcomes between the two approaches. This perspective posits that long-term survival relies less on the platform itself and more on the "surgeon factor"-specifically, the tenacity for radical lymph node dissection. While RATS imposes higher costs, its technical advantages may lower the barrier to achieving standardized, high-quality dissection, effectively "democratizing" surgical precision. Consequently, the choice of approach should not be binary but tailored to anatomical complexity and surgeon proficiency. Rather than forcing a transition, future paradigms must focus on leveraging technology to minimize performance variability while maintaining cost-effectiveness in a value-based healthcare system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.